Active Symptom Control

OTHER3 trials

Sponsors

The Christie NHS Foundation Trust, Wales Cancer Trials Unit, University Hospital Southampton NHS Foundation Trust

Conditions

Ampullary CancerBiliary Tract CancerCholangiocarcinomaGallbladder CancerMesotheliomaMesothelioma, Malignant

Phase 2

Vinorelbine in Mesothelioma

CompletedNCT02139904

Wales Cancer Trials UnitMesothelioma

Start: 2016-03-01End: 2021-03-17Updated: 2021-10-12

Niraparib Efficacy in Patient With Unresectable Mesothelioma

CompletedNCT05455424

University Hospital Southampton NHS Foundation TrustMesothelioma, Malignant

Start: 2022-07-11End: 2025-01-31Updated: 2025-05-15

Phase 3

Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers

CompletedNCT01926236

The Christie NHS Foundation TrustAmpullary Cancer, Biliary Tract Cancer, Cholangiocarcinoma +1

Start: 2014-02-28End: 2019-01-31Updated: 2020-01-28

Related Papers

Abstract CT263: Efficacy and multiomic analysis of Niraparib in relapsed mesothelioma: NERO a randomized phase II trial

Cancer Research2025-04-251 citations

A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.

2024-08-2119 citations

Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres

BMJ Open2023-11-014 citations

A randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO.

Journal of Clinical Oncology2023-06-011 citations

Significance of alterations in DNA damage repair (DDR) genes in advanced biliary cancers (ABCs) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 trial.

Journal of Clinical Oncology2023-01-245 citations

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial.

2022-05-1919 citations

A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma.

Journal of Clinical Oncology2021-05-2032 citations

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.

2021-03-30533 citations

Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results.

2020-11-1674 citations

Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer

Journal for ImmunoTherapy of Cancer2020-05-01140 citations

Selected Abstracts from the 2019 NCRI Cancer Conference of National Cancer Research Institute

British Journal of Cancer2019-10-042 citations

ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

Journal of Clinical Oncology2019-05-20226 citations

CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial

Trials2018-04-1845 citations